Home > Call For Paper > Novel Anticoagulants and Antiplatelet Agents

Novel Anticoagulants and Antiplatelet Agents

Novel anticoagulants and antiplatelet agents are a class of drugs designed to prevent blood clot formation in patients at risk of thrombotic events, such as stroke, heart attack, or deep vein thrombosis (DVT). These drugs work by targeting specific pathways in the coagulation cascade or platelet activation process to reduce clotting. Unlike traditional anticoagulants (like warfarin) and antiplatelet drugs (like aspirin), novel agents tend to offer benefits like more predictable effects, fewer drug interactions, and easier dosing schedules.

Key Topics:

  • Direct Oral Anticoagulants (DOACs)
  • Targeted Antiplatelet Therapy
  • Anticoagulants and Platelet Inhibition in Cardiovascular Disease
  • Novel Oral Anticoagulants (NOACs) in Special Populations
  • Reversal Agents for Novel Anticoagulants
  • Novel Anticoagulants in Cancer
  • Clinical Trial Design and Outcome Measures in Anticoagulation Therapy
  •  Safety and Efficacy in Real-World Populations
  • Long-Term Safety Data
  • Reversal Agents for New Anticoagulants
  • Combination Therapies
  • Personalized Medicine and Targeted Therapy
  • Novel Anticoagulants in Cancer Treatment
  • The Role of NOACs in Atrial Fibrillation
  • Impact on Bleeding Risk and Management
  • Cost-Effectiveness of Novel Anticoagulants
  • Biosimilars for Novel Anticoagulants

Related Tags: Anticoagulant Drugs | Direct Oral Anticoagulants | Platelet Inhibitors | Thromboprophylaxis | Drug Mechanisms | Clinical Trials in Anticoagulation | Patient Monitoring | Blood Clot Prevention | Thrombosis Management

Related Societies: Society of Cardiovascular Patient Care | Thrombosis Canada

 

SUBMIT ABSTRACT
  +1-404-759-8307
Subscribe To Our Newsletter
418184
TOP